← Back to Search

PI3K Inhibitor

Alpelisib + Fulvestrant for Endometrial Cancer

Phase 2
Recruiting
Research Sponsored by GOG Foundation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Negative serum pregnancy test and practicing highly effective contraception for patients of childbearing potential
Patients must have endometrioid histology (all grades allowed) based on hysterectomy or biopsy specimen and have positive expression of ER and oncogenic PIK3CA mutation per criteria below.
Must not have
Active bacterial, fungal, or detectable viral infection
Active bleeding or pathologic conditions with high risk of bleeding
Timeline
Screening 3 weeks
Treatment Varies
Follow Up side effects are monitor from the start of treatment to discontinuation of treatment assessed every 4 weeks. patients are treated until disease progression and are followed for 5 years.
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a combination of two drugs, alpelisib and fulvestrant, in patients with a specific type of endometrial cancer. These patients have a genetic mutation (PIK3CA) and their cancer grows in response to estrogen. Alpelisib targets the mutation, while fulvestrant blocks estrogen, aiming to stop cancer growth. Alpelisib is the first drug of its kind approved for use with fulvestrant based on its effectiveness in treating similar types of cancer.

Who is the study for?
This trial is for adults with recurrent or primary endometrioid endometrial cancer that's ER-positive and PIK3CA-mutated. Participants must have measurable disease, be recovered from prior treatments, have good performance status (ECOG 0-1), controlled blood sugar levels, and adequate organ function. They can't have had certain previous inhibitors, other cancer types or treatments, uncontrolled diabetes type II, serious infections or conditions that could interfere with the study.
What is being tested?
The trial tests a combination of an alpelisib pill and fulvestrant injection in patients to see how well it works against specific mutations in endometrial cancer. The main goal is to measure the objective response rate (ORR) - basically how many patients see their tumors shrink or disappear after treatment.
What are the potential side effects?
Possible side effects include reactions at the injection site for fulvestrant, high blood sugar levels due to alpelisib which may require monitoring and management of diet or medication adjustments. Other common issues might involve digestive problems like nausea or diarrhea.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am not pregnant and use effective birth control.
Select...
My endometrial cancer is ER positive and has a PIK3CA mutation.
Select...
I have recovered from the major side effects of my cancer treatments.
Select...
My endometrial cancer is advanced, persistent, or recurrent and cannot be cured by surgery or radiotherapy.
Select...
I have at least one tumor that can be measured with scans or exams.
Select...
I have had only one chemotherapy treatment before.
Select...
My endometrial cancer is advanced, persistent, or recurrent and cannot be cured by surgery or radiotherapy.
Select...
My cancer has come back or gotten worse, confirmed by tests.
Select...
My cancer is endometrioid with positive estrogen receptors and a PIK3CA mutation.
Select...
I am fully active or can carry out light work.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I currently have an active infection.
Select...
I am currently experiencing active bleeding or have a condition that greatly increases my risk of bleeding.
Select...
I have a digestive issue that affects how my body absorbs medication.
Select...
My cancer is one of the specified types affecting the uterus.
Select...
My brain metastases do not meet the study's requirements.
Select...
I have taken drugs targeting PIK3CA, PI3K, mTOR, or AKT before.
Select...
I have had hormonal therapy for endometrial cancer.
Select...
I haven't had major surgery or recovered from its major side effects within the last 14 days.
Select...
I have type 1 diabetes or my type 2 diabetes is not under control.
Select...
I do not have serious health issues that would stop me from joining this study.
Select...
I understand and can follow the study's instructions and requirements.
Select...
I have not had any other cancer besides this one in the last 5 years.
Select...
I have a known heart condition.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~response to treatment is assessed by recist version 1.1 criteria every 8 weeks with ct scan or mri through completion of treatment (complete or partial response). patients receive treatment until disease progression and are followed for 5 years.
This trial's timeline: 3 weeks for screening, Varies for treatment, and response to treatment is assessed by recist version 1.1 criteria every 8 weeks with ct scan or mri through completion of treatment (complete or partial response). patients receive treatment until disease progression and are followed for 5 years. for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Response rate
Secondary study objectives
Drug Toxicity (Side Effects)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Apelisib and FulvestrantExperimental Treatment2 Interventions
alpelisib 300mg orally daily of each 28-day cycle fulvestrant 500mg IM on Day 1 and Day 15 of Cycle 1, then 500mg IM on Day 1 of each 28-day cycle.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fulvestrant injection
2023
Completed Phase 1
~50

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for endometrial cancer, such as PI3K inhibitors and estrogen receptor antagonists, work by targeting specific pathways that drive cancer growth. PI3K inhibitors like Alpelisib block the PI3K/AKT/mTOR pathway, which is often overactive in cancer cells due to mutations, thereby reducing cell proliferation and inducing apoptosis. Estrogen receptor antagonists like Fulvestrant bind to and degrade estrogen receptors, blocking the estrogen signaling that promotes the growth of hormone receptor-positive cancer cells. This dual approach is particularly effective for patients with PIK3CA mutations and estrogen receptor-positive tumors, addressing both genetic and hormonal factors driving the cancer.
Efficacy of afatinib in a <i>HER2</i> amplification-positive endometrioid adenocarcinoma patient- a case report.A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.

Find a Location

Who is running the clinical trial?

GOG FoundationLead Sponsor
46 Previous Clinical Trials
17,599 Total Patients Enrolled
NovartisIndustry Sponsor
1,638 Previous Clinical Trials
2,774,152 Total Patients Enrolled
Stephanie Gaillard, MDStudy ChairGOG Foundation
3 Previous Clinical Trials
91 Total Patients Enrolled

Media Library

Alpelisib (PI3K Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05154487 — Phase 2
Uterine Cancer Research Study Groups: Apelisib and Fulvestrant
Uterine Cancer Clinical Trial 2023: Alpelisib Highlights & Side Effects. Trial Name: NCT05154487 — Phase 2
Alpelisib (PI3K Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05154487 — Phase 2
~25 spots leftby Apr 2025